Skye Bioscience CEO Punit Dhillon joins Natalie Stoberman in the Proactive studio to share November's milestones.
Dhillon says the company has submitted an investigational new drug application, and initiated the first in-human Phase 1 clinical trial for its SBI-100 glaucoma drug.